Guo's Visceral Arteries Reconstruction: First in Man Study

Inclusion Criteria

• Age ≥18 and ≤80 years;
• Patients diagnosed with type Crawford I-V thoracoabdominal aortic aneurysmsa and pararenal abdominal aortic aneurysm, and should meet at least one of the following conditions:
• The maximum diameter of thoracoabdominal aortic aneurysms and pararenal abdorminal aortic aneurysm > 50 mm;
• Rapid growth of sac >5 mm in diameter in the most recent 6 months;
• Definite symptoms of abdominal pain and low back pain associated with thoracicabdominal aortic aneurysms.
• Patients with four indispensable reno-visceral arteries including superior mesenteric artery, celiac trunk and bilaterial renal arteries.
• Proximal landing zone 20-36 mm in diameter;
• Proximal landing zone ≥25 mm in length;
• If distal landing zone in abdominal aorta, distal landing zone should be 12-36mm in diameter and ≥15 mm in length.
• The visceral vascular branches landing zone 6~13 mm in diameter and ≥15 mm in length;
• The renal artery landing zone 4.5~9 mm in diameter and ≥15 mm in length;
• Patients who using the abdominal aortic bifurcation stent graft system should also meet the following criteria:
• The ilac artery landing zone 7 ~25 mm in diameter;
• The ilac artery landing zone ≥15 mm in length;
• Patients with appropriate iliacofemoral access and at least one patent upper extremity access;
• Patients who can understand the purpose of the trial, volunntarily participate and sign the informed consent form, and are willing to complete the follow-up according to the requirements of the protocol;

Exclusion Criteria

• Ruptured aortic aneurysm in unstable haemodynamic condition;
• Aneurysmal aortic dissection;
• Infected or mycotic aortic aneurysm;
• Requiring simultaneous coverage or embolisation for bilateral internal iliac arteries;
• Severe stenosis, calcification, or mural thrombus at stent-graft landing zone;
• Diagnosis of acute coronary syndrome within 6 months;
• Patients with any transient ischemic attack (TIA) or ischemic stroke within 3 months;
• An allergic history for contrast agents, anticoagulants, antiplatelet drugs, stent graft or materials of delivery system；
• Patients with connective tissue diseases;
• Patients with takayasu arteritis;
• Patients with serious vital organ dysfunction or other serious disease;
• Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol/L;
• Severe pulmonary insufficiency who cannot tolerate general anaesthesia;
• Severe coagulation dysfunction;
• Undergone major surgical or interventionic surgery within 30 days before surgery;
• Patients whose systemic or local infection may increase the risk of intravascular graft infection;
• Planning pregnancy, pregnancy, or breastfeeding;
• The patient participated in other clinical trials or not completed or withdrawn from other clinical trials within the last 3 months at the time of screening period ;
• Life expectancy less than 1 year;
• Patients not appropriate for endovascular repair based on the investigators' clinical judgement.